Clinical Studies

Information about the availability of clinical studies of VNS Therapy


Cyberonics is currently sponsoring a post market clinical study on VNS Therapy in patients with Treatment Resistant Depression. Enrollment for this study is currenlty on hold. To learn more about this study, please go to the following website: http://www.clinicaltrials.gov/ct/show/NCT00305565

TRD Registry

Cyberonics is currently sponsoring the TRD Registry, the first registry specifically for patients with TRD.  By collecting comprehensive data from > 2000 patients over 2 to 5 years, the TRD Registry will support rigorous analyses and substantially improve the understanding of TRD and available treatments.  The primary objective of the TRD Registry is to follow the clinical course and outcome for patients with TRD treated with and without adjunctive VNS Therapy.  The TRD registry is currently enrolling participants. To learn more about the TRD Registry, please go to the following website: http://www.clinicaltrials.gov/ct/show/NCT00320372 or to www.TRDRegistry.org to download an informational brochure.

    
  Enroll in the Connections program

See how VNS therapy has helped others
  Meet Charles
See more testimonials

Insurance
information >>>

 
   
© Cyberonics, Inc. 2007  
       
  UNITED STATES INDICATION FOR USE:
The VNS Therapy System is indicated for use as an adjunctive therapy in reducing the frequency of seizures in adults and adolescents over 12 years of age with partial onset seizures, which are refractory to antiepileptic medications.

VNS Therapy (or the VNS Therapy System) is indicated for the adjunctive long-term treatment of chronic or recurrent depression for patients over the age of 18 who are experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments.